Precision BioSciences Extends Term Loan Maturity to December 2029
DTIL sits 79% above its 52-week low of $3.53.
Summary
Precision BioSciences amended its loan agreement with Banc of California, extending the maturity date of its term loan by over two years to December 31, 2029.
Key Events · Financing and Capital Events · DTIL
-
Loan Maturity Extended
The company amended its loan agreement with Banc of California, extending the maturity date of its term loan from June 30, 2027, to December 31, 2029.
-
Enhanced Financial Flexibility
This extension provides Precision BioSciences with over two additional years of financial runway, reducing immediate refinancing pressures and supporting its long-term operational plans.
Analysis · DTIL · Life Sciences
This amendment significantly improves Precision BioSciences' financial flexibility by pushing out a key debt maturity. Extending the term loan from mid-2027 to end-2029 reduces near-term refinancing risk and provides a longer runway for the company to execute its strategic initiatives, building on its recently reaffirmed cash runway through 2028. This indicates continued lender confidence in the company's prospects.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DTIL was trading at $6.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.8M. The 52-week trading range was $3.53 to $8.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.